ESO Lymphoma Course
A

Should We Add Other Agents Like Obinutuzumab, Lenalidomide, Bortezomib or Ibrutinib to R-CHOP? How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis?

By ESO Lymphoma Course FEATURING Andrew Davies
September 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

10:37
Amgen Oncology

Multiple Myeloma: Importance of Proteasome Inhibition at First Relapse

Feat. J. Abbas

Related Content

AUTOPLAY
Moffitt Cancer Center

16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Sat, Jan 18, 2020
The University of Kansas Cancer Center

KU ASH 2019 Review: Current Updates in Hematologic Diseases

Sat, Jan 18, 2020
UChicago Medicine Comprehensive Cancer Center

UChicago Annual Updates from ASH 2019

Fri, Feb 28, 2020
8th ESO-SIOP Europe Masterclass in Paediatric Oncology

8th ESO-SIOP Europe Masterclass in Paediatric Oncology

Sat, Jun 6, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Mar 21, 2020
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Fri, Feb 7, 2020
15:50
Indy Hematology Review

Treatment Algorithm for DLBCL

Feat. J. Leonard
17:49
Jonathan Friedberg

How to Improve on RCHOP for DLBCL: Role of Novel Agents

10:46
2018 Pan Pacific Lymphoma Conference

New Approaches to Initial treatment of DLBCL: R-CHOP +

Feat. N. Bartlett
15:30
2018 Pan Pacific Lymphoma Conference

Challenges of Treating HGBCL Patients with Comorbidities: Who is "FIT" f...

Feat. L. Sehn
22:02
2018 Pan Pacific Lymphoma Conference

New Antibody-Drug Conjugates

Feat. B. Kahl
10:00
2018 Pan Pacific Lymphoma Conference

The Tumor Microenvironment Using Immune Checkpoint Inhibitors

Feat. J. Gribben
09:28
2018 Pan Pacific Lymphoma Conference

Novel Cell Pathway Targeted Agents for Relapsed DLBCL

Feat. J. Vose
19:22
2018 Pan Pacific Lymphoma Conference

Challenges of Treating HGBCL Patients with Comorbidities: Anthracyclines...

Feat. L. Sehn
22:17
ESO Lymphoma Course

First Line DLBCL: How Many Cycles of RCHOP? Improving Outcomes of CHOP: ...

Feat. A. Davies
12:47
2019 Scripps MD Anderson's Oncology Update

Lymphoma Practicing Changing ASCO19 Studies: Novel Agents Prior to R-Cho...

Feat. A. Saven
22:03
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Frontline Strategy for Aggressive Lymphoma - Can we Replace RCHOP?

Feat. J. Westin
16:44
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

How I Treat Double Hit Lymphoma

Feat. K. Dunleavy
10:59
2018 Pan Pacific Lymphoma Conference

A Brief Introduction to the Evolving Role of Genomics in NHL with Case E...

Feat. D. Zelenetz
17:51
2018 Pan Pacific Lymphoma Conference

Optimum Therapy for Standard Risk High Grade - DLBCL

Feat. N. Bartlett
17:33
2018 Pan Pacific Lymphoma Conference

Novel-Novel Drug Combinations in B-cell Malignancies

Feat. K. Dunleavy
28:21
John Pagel

Treatment of Newly Diagnosed DLBCL

10:10
Northwestern Medicine Oncology and Hematology

Treatment and Management Strategies for Diffuse Large B-cell Lymphoma Di...

Feat. L. Gordon
15:08
2018 Pan Pacific Lymphoma Conference

Immune Evasion and Engagement in Lymphoma: The Mechanisms of Impairment ...

Feat. S. Ansell
13:17
2018 Pan Pacific Lymphoma Conference

Novel Cell Pathway Targeted Agents for DLBCL: Determining Cell-of-Orgin

Feat. J. Vose
15:54
2018 Pan Pacific Lymphoma Conference

Lymphoma Immunotherapy: Monoclonal Antibodies and Mechanism of Action, A...

Feat. L. Zitella